All patients
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Immunostimulants drugs in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.76 [0.61 ; 0.95 ] Bennett-Guerrero, 2021, CONTAIN COVID-19, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, O’Donnell, 2021, PlasmAr, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 7 0% 4,316 moderate not evaluable death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CCAP-2, 2021 2.03 [0.61; 6.77]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Libster, 2020 0.50 [0.09; 2.71]
Lopardo, 2021 0.57 [0.24; 1.37]
NCT04442191, 2021 0.11 [0.00; 143.68]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
0.78 [0.66 ; 0.92 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CCAP-2, 2021, CONTAIN COVID-19, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Libster, 2020, Lopardo, 2021, NCT04442191, 2021, O’Donnell, 2021, PlasmAr, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 16 0% 7,233 moderate low deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.83 [0.64 ; 1.07 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, Baldeon, 2022, Bennett-Guerrero, 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020 6 0% 3,319 moderate serious clinical deteriorationdetailed results CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
Libster, 2020 0.52 [0.29; 0.94]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
0.71 [0.44 ; 1.13 ] CONTAIN COVID-19, 2021, Libster, 2020, Synairgen SG016, 2020 3 55% 1,202 moderate not evaluable clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.05 [0.96 ; 1.15 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, Bennett-Guerrero, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Synairgen SG016, 2020 9 14% 4,156 moderate not evaluable clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
1.01 [0.79 ; 1.29 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
O’Donnell, 2021 1.38 [0.73; 2.61]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.77 [0.94 ; 3.32 ] Bennett-Guerrero, 2021, O’Donnell, 2021, Synairgen SG016, 2020 3 35% 398 moderate not evaluable clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
0.98 [0.76 ; 1.26 ] ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022 2 0% 899 moderate not evaluable clinical improvement (time to event analysis only)detailed results Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
1.01 [0.91 ; 1.13 ] Bennett-Guerrero, 2021, Kalil (ACTT-3), 2021, O’Donnell, 2021, PlasmAr, 2020 4 0% 1,600 moderate not evaluable death or ventilationdetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.64 [0.45 ; 0.90 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 2 0% 1,197 moderate not evaluable hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.21 [0.85 ; 1.72 ] ACTIV-3/TICO LY-CoV555 , 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 3 58% 1,612 low not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
1.03 [0.53 ; 2.00 ] O’Donnell, 2021, PlasmAr, 2020 2 0% 556 low not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable ICU admissiondetailed results Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
0.60 [0.33 ; 1.10 ] Libster, 2020, Lopardo, 2021 2 0% 401 moderate not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
1.12 [0.97 ; 1.28 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, Synairgen SG016, 2020 4 7% 1,129 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable serious adverse eventsdetailed results ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
0.97 [0.71 ; 1.33 ] ITAC, 2022, Jagannathan, 2020, O’Donnell, 2021, PlasmAr, 2020 4 10% 1,251 moderate not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
1.33 [0.63 ; 2.78 ] Jagannathan, 2020 1 0% 120 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-07 19:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567
- roots T: 290
